NRx Pharmaceuticals

Company Overview

Snapshot

Founded in October 2014 by Daniel C. Javitt and Jonathan C. Javitt, NRx Pharmaceuticals operates with 11–50 employees. The company has raised a total of $176.18 million across 7 funding rounds. In May 2021, NRx Pharmaceuticals completed a SPAC merger with Big Rock Partners Acquisition Corporation, achieving a valuation of $1.5 billion and subsequently began trading on NASDAQ.

Business overview

NRx Pharmaceuticals is a specialized biopharmaceutical company focused on addressing high unmet medical needs in central nervous system (CNS) diseases. The company develops therapies for conditions such as severe bipolar depression with suicidality and post-traumatic stress disorder (PTSD). Its pipeline leverages a proprietary, dual-targeted mechanism of action that modulates NMDA and 5HT2A receptors. NRx Pharmaceuticals operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving healthcare providers and patients globally.

Strategic signal

In June 2026, NRx Pharmaceuticals announced the pricing of a public offering of common stock, following a proposed public offering earlier in the month. This indicates the company's continued efforts to raise capital through public markets to support its ongoing drug development and commercialization strategies, signaling active financial maneuvering to investors.

Company Intelligence Q&A

What significant regulatory milestone did NRx Pharmaceuticals achieve in May 2026?

In May 2026, NRx Pharmaceuticals announced FDA clearance to proceed with a clinical trial of NRX-101 in combination with robotic-enabled Transcranial Magnetic Stimulation for patients with depression and suicidality.

What strategic partnership did NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, announce in March 2026?

In March 2026, HOPE Therapeutics, an NRx Pharmaceuticals subsidiary, announced a strategic partnership with Emobot to integrate its AI-powered 'Depression Thermometer' across its interventional psychiatry network.

What was a key financial development for NRx Pharmaceuticals in December 2025?

In December 2025, NRx Pharmaceuticals announced the elimination of all balance sheet debt following an equity conversion of $5.4 million owed to Anson Funds, LLC, positioning the company for accelerated growth.

What was the outcome of NRx Pharmaceuticals' FDA interaction regarding NRX-100 in February 2026?

In February 2026, NRx Pharmaceuticals announced a path to New Drug Application (NDA) with Real World Data and a broader proposed indication for NRX-100 (ketamine) following a Type C FDA meeting, indicating positive progress towards drug approval.

What acquisition did NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, complete in September 2025?

In September 2025, HOPE Therapeutics, an NRx Pharmaceuticals subsidiary, completed the acquisition of Dura Medical, a provider of interventional psychiatry services in Florida, expanding its network of clinics.